Rosalind Advisors’s Definium Therapeutics DFTX Stock Holding History

Rosalind Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-125,000	Closed	-$2.36M	–	40
2026 Q1	$2.36M	Sell	125,000 -625,000	-83%	-$10.6M	0.95%	24
2025 Q4	$10M	Hold	750,000	–	–	3.53%	15
2025 Q3	$8.84M	Buy	750,000 +330,000	+79%	+$3.08M	3.02%	15
2025 Q2	$2.73M	Hold	420,000	–	–	1.29%	22
2025 Q1	$2.46M	Buy	+420,000	New	+$3.01M	1.19%	23

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Rosalind Advisors's DFTX Position: Q2 2026 in Review

Rosalind Advisors sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 125,000 shares — an estimated $2.36M sold.

Rosalind Advisors first reported a position in DFTX in Q1 2025 and held it in 5 quarters. The position peaked at $10M in Q4 2025. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Rosalind Advisors reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
Rosalind Advisors sold 125,000 Definium Therapeutics shares in Q2 2026, an estimated $2.36M.
Rosalind Advisors first reported a position in Definium Therapeutics in Q1 2025 and held it in 5 quarters.
Rosalind Advisors's Definium Therapeutics position peaked at $10M in Q4 2025.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.